Latest Healthcare Research Reports

Tag: choroidal neovascularization market growth

  • Choroidal Neovascularization Market Forecast Highlights Expansion From $4.5 Billion To $5.98 Billion Through 2030

    Choroidal Neovascularization Market Forecast Highlights Expansion From $4.5 Billion To $5.98 Billion Through 2030

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Choroidal Neovascularization Market Forecast: What Market Value Is Expected By 2030?

    The market for choroidal neovascularization has experienced robust expansion recently, projected to advance from $4.18 billion in 2025 to $4.5 billion in 2026, demonstrating a compound annual growth rate of 7.7%. This expansion during the preceding period was driven by several key factors, including a heightened incidence of age-related macular degeneration, an increase in cases of diabetic eye disease, the proliferation of ophthalmology clinics, the accessibility of anti-angiogenic therapies, and advancements in the ability to diagnose retinal conditions.

    The market for treating choroidal neovascularization is poised for significant expansion in the coming years, projected to reach $5.99 billion by 2030 with a compound annual growth rate of 7.4%. This upward trajectory during the forecast period is underpinned by several key factors, including a growing elderly demographic, a heightened emphasis on timely ophthalmic interventions, the proliferation of combined treatment strategies, increased funding for researching retinal diseases, and a greater uptake of customized treatment plans. Emerging trends within this timeframe are expected to include a wider application of anti-VEGF therapies, more frequent utilization of treat-and-extend regimens, a surge in demand for early diagnosis of CNV, advancements in retinal imaging technologies, and a concentrated effort on therapies aimed at preserving vision.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

    Choroidal Neovascularization Market Expansion Supported By Key Demand Factors

    The expanding incidence of age-related macular degeneration (AMD) is anticipated to be a significant catalyst for the expansion of the choroidal neovascularization (CNV) market. AMD, a condition impacting vision primarily in older demographics, involves the progressive deterioration of the macula and results in a loss of central sight. This escalating prevalence is linked to an aging global populace, extended lifespans, shifts in lifestyle habits, genetic predispositions, and heightened susceptibility to environmental hazards. Choroidal neovascularization plays a crucial role in supporting AMD patients by facilitating the progression of the “wet” form of the disease, characterized by the formation of aberrant blood vessels under the retina, which leads to worsening vision. Effective management of CNV and mitigation of AMD progression, essential for preserving central vision, frequently necessitates sophisticated interventions like anti-VEGF treatments. Illustratively, the UHN Foundation, Canada’s official fundraising entity, identified AMD as the leading contributor to severe, permanent vision impairment in individuals exceeding 50 years of age as of 2025. With more than 200 million individuals currently affected worldwide, this figure is forecasted to reach 288 million by 2040, thereby underscoring how the growing burden of age-related macular degeneration directly fuels the expansion of the choroidal neovascularization market.

    #Choroidal Neovascularization Market Segment Landscape And Growth Potential

    The choroidal neovascularization market covered in this report is segmented –

    1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

    3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

    4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

    Subsegments:

    1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

    3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

    4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

    5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

    6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

    7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

    8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

    Choroidal Neovascularization Market Growth Trends Influencing Competitive Dynamics

    Within the choroidal neovascularization sector, leading enterprises are dedicated to pioneering advanced treatments, including photodynamic therapy, aiming to equip eye care practitioners with accurate and effective interventions that enhance patient results and the administration of care. Photodynamic therapy (PDT) involves a medical procedure employing a light-activated photosensitizing substance to selectively eliminate aberrant or malignant cells. To illustrate, in February of 2023, Bausch & Lomb, a healthcare entity based in Canada, in conjunction with Modulight, a Finnish biomedical firm, revealed the FDA clearance of their ML6710i photodynamic laser system. This therapeutic approach has received approval for utilization alongside Bausch + Lomb’s established VISUDYNE therapy, specifically formulated for combating choroidal neovascularization associated with age-related macular degeneration (AMD). The cutting-edge, portable ophthalmic laser provides a focused method for addressing the proliferation of abnormal blood vessels within the eye, thereby contributing to the prevention of disease advancement and the safeguarding of visual acuity.

    Choroidal Neovascularization Market Competitive Landscape: Who Are The Leading Companies?

    Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated

    Access The Complete Choroidal Neovascularization Market Report:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    Choroidal Neovascularization Market Leading Geography: Which Region Generates The Most Revenue?

    North Americawas the largest region in the choroidal neovascularization market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Choroidal Neovascularization Market Insights Exploring Expansion Opportunities Through 2030

    Choroidal Neovascularization Market Insights Exploring Expansion Opportunities Through 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Market Value Expansion Is Expected For The Choroidal Neovascularization Market Over The Forecast Period?

    The choroidal neovascularization market has experienced robust growth recently. It is projected to increase from $4.18 billion in 2025 to $4.5 billion in 2026, representing a compound annual growth rate (CAGR) of 7.7%. This historic expansion has been driven by factors such as the increasing prevalence of age-related macular degeneration, a rise in diabetic eye disease cases, the expansion of ophthalmology clinics, the availability of anti-angiogenic drugs, and improvements in retinal diagnostic capabilities.

    The choroidal neovascularization market is projected to demonstrate significant growth over the next few years. It is expected to expand to $5.99 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.4%. This expansion during the forecast period can be attributed to an aging global population, a heightened emphasis on timely ophthalmic intervention, the wider adoption of combination therapy approaches, increasing financial commitments to retinal disease research, and the rising implementation of personalized treatment protocols. Prominent trends within this period include the increased uptake of anti-VEGF therapies, a growing reliance on treat-and-extend regimens, a surging requirement for early CNV diagnosis, the broader application of advanced retinal imaging techniques, and an intensified focus on therapies aimed at preserving vision.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

    Which Growth Drivers Are Expected To Support The Choroidal Neovascularization Market Forward?

    The increasing incidence of age-related macular degeneration (AMD) is anticipated to drive the expansion of the choroidal neovascularization (CNV) market in the future. Age-related macular degeneration (AMD) is an ocular condition characterized by progressive harm to the macula, resulting in the impairment of central vision, predominantly among the elderly. The growing occurrence of age-related macular degeneration (AMD) stems from an aging demographic, extended longevity, evolving lifestyle habits, hereditary predispositions, and heightened vulnerability to environmental hazards. Choroidal neovascularization (CNV) plays a role in aiding age-related macular degeneration (AMD) sufferers through its involvement in the emergence of wet AMD, a condition where the proliferation of atypical blood vessels under the retina causes a decline in vision, necessitating sophisticated interventions like anti-VEGF therapy to control choroidal neovascularization (CNV) and decelerate the advancement of age-related macular degeneration (AMD), thereby helping to maintain central vision for those impacted. For example, by 2025, the UHN Foundation, Canada-Based official fundraising arm, reports that age-related macular degeneration (AMD) will be the leading reason for substantial, permanent vision impairment in people aged over 50. While it currently impacts more than 200 million individuals globally, this figure is predicted to reach 288 million by 2040. Consequently, the growing incidence of age-related macular degeneration is fueling the expansion of the choroidal neovascularization market.

    Which Segment-Based Categories Are Covered In The Choroidal Neovascularization Market?

    The choroidal neovascularization market covered in this report is segmented –

    1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

    3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

    4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

    Subsegments:

    1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

    3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

    4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

    5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

    6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

    7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

    8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

    What Trends Are Influencing The Choroidal Neovascularization Market?

    Major entities operating in the choroidal neovascularization market are concentrating on creating innovative treatments, such as photodynamic therapy, to provide eye care professionals with precise, efficient treatment alternatives that improve patient outcomes and the delivery of care. Photodynamic therapy (PDT) is a medical process that utilizes a photosensitizing agent activated by light to specifically target and destroy abnormal or cancerous cells. For example, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, disclosed the ML6710i photodynamic laser, which was approved by the Food and Drug Administration, a US-based federal agency. This therapy is authorized for use with Bausch + Lomb’s VISUDYNE therapy, which is specifically designed to treat choroidal neovascularization caused by age-related macular degeneration (AMD). This modern, mobile ophthalmic laser provides a targeted approach for treating abnormal blood vessels in the eye, helping to prevent further disease progression and preserve vision.

    Which Organizations Are Involved In The Choroidal Neovascularization Market?

    Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated

    Access The Complete Choroidal Neovascularization Market Report:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    Which Area Represents The Largest Portion Of The Choroidal Neovascularization Market?

    North America was the largest region in the choroidal neovascularization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Choroidal Neovascularization Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

    Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2026, By The Business Research Company

    Cartilage Repair Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cartilage-repair-global-market-report

    Knee Cartilage Repair Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/knee-cartilage-repair-global-market-report

    Regenerative Medicine For Cartilage Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/regenerative-medicine-for-cartilage-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Choroidal Neovascularization Market: Key Developments Driving Growth

    Choroidal Neovascularization Market: Key Developments Driving Growth

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Much Growth In Market Value Is Expected For The Choroidal Neovascularization Market Between 2026 And 2030?

    The market size for choroidal neovascularization has experienced substantial expansion in recent years. This market is anticipated to expand from $4.18 billion in 2025 to $4.5 billion in 2026, progressing at a compound annual growth rate (CAGR) of 7.7%. The historical growth can be linked to several factors, including the increasing occurrence of age-related macular degeneration, a rise in diabetic eye disease cases, the proliferation of ophthalmology clinics, the accessibility of anti-angiogenic drugs, and improvements in retinal diagnostic capabilities.

    The choroidal neovascularization market is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $5.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. Factors contributing to this growth during the projected period include an expanding aging demographic, heightened emphasis on prompt ophthalmic interventions, the broadening of combination therapy methods, increasing investments dedicated to retinal disease research, and a greater uptake of personalized treatment protocols. Key trends shaping the market within the forecast timeframe encompass the wider acceptance of anti-VEGF therapies, the increasing application of treat-and-extend regimens, a rising need for early CNV diagnosis, the proliferation of sophisticated retinal imaging techniques, and an intensified focus on therapies aimed at preserving vision.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    Which Primary Drivers Are Impacting The Choroidal Neovascularization Market Growth?

    The increasing occurrence of age-related macular degeneration (AMD) is anticipated to drive the expansion of the choroidal neovascularization (CNV) market in the future. AMD is an ocular condition that progressively impairs the macula, resulting in the loss of central vision, predominantly among older individuals. This surge in AMD cases stems from an aging demographic, extended life spans, evolving lifestyles, genetic predispositions, and heightened environmental risk exposure. CNV plays a role in patients with AMD by fostering the emergence of wet AMD, a condition characterized by the formation of aberrant blood vessels under the retina, causing visual decline. Managing CNV and retarding AMD progression often necessitates advanced therapies like anti-VEGF treatment to help maintain central vision for those afflicted. For instance, the UHN Foundation, Canada-Based official fundraising arm, stated that by 2025, AMD will be the leading cause of considerable, permanent vision impairment in people aged over 50. Presently impacting more than 200 million individuals worldwide, this figure is predicted to climb to 288 million by 2040. Consequently, the expanding incidence of age-related macular degeneration is fueling the growth of the choroidal neovascularization market.

    Which Segment Types Are Examined In The Choroidal Neovascularization Market Segment Study?

    The choroidal neovascularization market covered in this report is segmented –

    1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

    3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

    4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

    Subsegments:

    1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

    3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

    4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

    5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

    6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

    7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

    8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

    Which Trends Are Shaping Growth In The Choroidal Neovascularization Market?

    Leading companies in the choroidal neovascularization market are prioritizing the development of innovative therapies, such as photodynamic therapy, to provide eye care professionals with precise, efficient treatment solutions that improve patient outcomes and enhance treatment delivery. Photodynamic therapy (PDT) functions as a medical procedure employing a photosensitizing agent activated by light to specifically target and destroy abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, alongside Modulight, a Finland-based biomedical company, announced the ML6710i photodynamic laser, which received approval from the Food and Drug Administration, a US-based federal agency. This therapy is approved for use with Bausch + Lomb’s VISUDYNE therapy, which is designed to treat choroidal neovascularization caused by age-related macular degeneration (AMD). This modern, mobile ophthalmic laser offers a targeted approach for treating abnormal blood vessels in the eye, thereby helping to prevent further disease progression and preserve vision.

    Which Players Are Part Of The Competitive Landscape Of The Choroidal Neovascularization Market?

    Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated

    Get The Full Choroidal Neovascularization Market Report:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    Which Geographic Region Dominates The Choroidal Neovascularization Market?

    North America was the largest region in the choroidal neovascularization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Choroidal Neovascularization Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2026, By The Business Research Company

    Ocular Hypertension Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/ocular-hypertension-treatment-global-market-report

    Intravascular Ultrasound Market Report 2026

    https://www.thebusinessresearchcompany.com/report/intravascular-ultrasound-global-market-report

    Vascular Imaging Market Report 2026

    https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • A Significant Growth Driver for the Choroidal Neovascularization Market Is the Increasing Prevalence Of Age-related Macular Degeneration Driving Market Growth

    A Significant Growth Driver for the Choroidal Neovascularization Market Is the Increasing Prevalence Of Age-related Macular Degeneration Driving Market Growth

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    How Will The Market Size Of The Choroidal Neovascularization Market Evolve From 2026 To 2030?

    The choroidal neovascularization market has seen substantial growth in recent years. It is anticipated to increase from $4.18 billion in 2025 to $4.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. This historical expansion can be linked to factors such as the increasing prevalence of age-related macular degeneration, a rise in diabetic eye disease cases, the expansion of ophthalmology clinics, the availability of anti-angiogenic drugs, and improved retinal diagnostic capabilities.

    The choroidal neovascularization market size is anticipated to undergo significant expansion in the next few years, projected to reach $5.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This expected growth within the forecast period is influenced by an increasing aging population, a rising emphasis on early ophthalmic intervention, the expansion of combination therapy approaches, growing investments in retinal disease research, and the increasing adoption of personalized treatment protocols. Prominent trends for the forecast period include the increasing adoption of anti-VEGF therapies, the rising use of treat-and-extend regimens, a growing demand for early CNV diagnosis, the expansion of advanced retinal imaging techniques, and an enhanced focus on vision preservation therapies.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

    What Drivers Are Influencing The Choroidal Neovascularization Market?

    The increasing incidence of age-related macular degeneration (AMD) is anticipated to drive the expansion of the choroidal neovascularization (CNV) market moving forward. Age-related macular degeneration (AMD) is an eye ailment that progressively damages the macula, culminating in central vision impairment, mainly affecting older individuals. The escalating prevalence of age-related macular degeneration (AMD) results from factors such as the aging population, extended life expectancy, alterations in lifestyle, genetic predisposition, and heightened exposure to environmental risks. Choroidal neovascularization (CNV) affects age-related macular degeneration (AMD) patients by facilitating the emergence of wet AMD, where the proliferation of anomalous blood vessels beneath the retina leads to a decline in vision, requiring sophisticated treatments like anti-VEGF therapy to manage choroidal neovascularization (CNV) and slow the advancement of age-related macular degeneration (AMD), ultimately safeguarding central vision in those impacted. For example, in 2025, as per the UHN Foundation, Canada-Based official fundraising arm, age-related macular degeneration (AMD) is identified as the principal cause of substantial, irreversible vision loss in individuals over 50. Currently impacting over 200 million people worldwide, this figure is projected to climb to 288 million by 2040. Consequently, the rising prevalence of age-related macular degeneration is fueling the growth of the choroidal neovascularization market.

    Which Segment Areas Are Covered In The Choroidal Neovascularization Market Analysis?

    The choroidal neovascularization market covered in this report is segmented –

    1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

    3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

    4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

    Subsegments:

    1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

    3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

    4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

    5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

    6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

    7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

    8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

    What Trends Are Advancing Progress In The Choroidal Neovascularization Market?

    Key companies operating in the choroidal neovascularization market are concentrating on developing innovative treatments, such as photodynamic therapy, to provide eye care professionals with accurate, efficient treatment options that improve patient outcomes and the delivery of care. Photodynamic therapy (PDT) is a medical procedure that employs a photosensitizing agent activated by light to specifically target and eliminate abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the ML6710i photodynamic laser, which received approval from the Food and Drug Administration, a US-based federal agency. This therapy is approved for use alongside Bausch + Lomb’s VISUDYNE therapy, designed to treat choroidal neovascularization resulting from age-related macular degeneration (AMD). This contemporary, mobile ophthalmic laser offers a targeted method for treating abnormal blood vessels in the eye, thereby helping to prevent further disease progression and preserve vision.

    Which Global Companies Are Actively Competing In The Choroidal Neovascularization Market?

    Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated

    Read the full choroidal neovascularization market report here:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    Which Regions Are Expected To Experience Rapid Expansion In The Choroidal Neovascularization Market?

    North America was the largest region in the choroidal neovascularization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Choroidal Neovascularization Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

    Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2026, By The Business Research Company

    Cartilage Repair Global Market Report

    https://www.thebusinessresearchcompany.com/report/cartilage-repair-global-market-report

    Knee Cartilage Repair Global Market Report

    https://www.thebusinessresearchcompany.com/report/knee-cartilage-repair-global-market-report

    Regenerative Medicine For Cartilage Global Market Report

    https://www.thebusinessresearchcompany.com/report/regenerative-medicine-for-cartilage-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Choroidal Neovascularization Market Insights Report: Opportunities and Drivers 2030

    Choroidal Neovascularization Market Insights Report: Opportunities and Drivers 2030

    Uncover key drivers, emerging technologies, and competitive movements shaping the choroidal neovascularization market from 2026–2035 with trusted insights from The Business Research Company

    What level of growth is expected in the Choroidal Neovascularization Market between 2026 and 2030?

    The choroidal neovascularization market size has demonstrated strong growth in recent years. It is anticipated to increase from $4.18 billion in 2025 to $4.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. This expansion observed during the historic period can be attributed to factors such as the increasing prevalence of age-related macular degeneration, rising diabetic eye disease cases, the expansion of ophthalmology clinics, the availability of anti-angiogenic drugs, and improved retinal diagnostic capabilities.

    The choroidal neovascularization market size is anticipated to experience robust expansion over the next few years. It is projected to reach $5.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This growth during the forecast period can be attributed to an increasing aging population, a rising emphasis on early ophthalmic intervention, the expansion of combination therapy approaches, growing investments in retinal disease research, and the increasing adoption of personalized treatment protocols. Significant trends for the forecast period include the increasing uptake of anti-VEGF therapies, the rising use of treat-and-extend regimens, a growing demand for early CNV diagnosis, the expansion of advanced retinal imaging techniques, and an enhanced focus on vision preservation therapies.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

    Which Drivers Are Expected To Impact The Choroidal Neovascularization Market During The Forecast Period?

    The growing incidence of age-related macular degeneration (AMD) is anticipated to drive the expansion of the choroidal neovascularization (CNV) market moving ahead. Age-related macular degeneration (AMD) refers to an ocular condition that progressively impairs the macula, resulting in the loss of central vision, predominantly among elderly individuals. This increasing prevalence of age-related macular degeneration (AMD) stems from factors such as an aging demographic, extended life expectancy, shifts in lifestyle, genetic predispositions, and heightened vulnerability to environmental hazards. Choroidal neovascularization (CNV) plays a role in patients with age-related macular degeneration (AMD) by fostering the onset of wet AMD, where the proliferation of aberrant blood vessels under the retina causes vision decline, necessitating advanced therapeutic interventions like anti-VEGF therapy to control choroidal neovascularization (CNV) and impede the advancement of age-related macular degeneration (AMD), thereby aiming to safeguard central vision for those impacted. For illustration, the UHN Foundation, Canada-Based official fundraising arm, reported that by 2025, age-related macular degeneration (AMD) stands as the principal reason for considerable, permanent vision impairment in persons exceeding 50 years of age. Globally, it currently impacts more than 200 million individuals, with projections indicating an increase to 288 million by 2040. Consequently, the expanding occurrence of age-related macular degeneration is fueling the expansion of the choroidal neovascularization market.

    Which Segments Are Driving Activity In The Choroidal Neovascularization Market?

    The choroidal neovascularization market covered in this report is segmented –

    1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

    3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

    4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

    Subsegments:

    1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

    3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

    4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

    5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

    6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

    7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

    8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

    How Are New Market Trends Shaping The Landscape Of The Choroidal Neovascularization Market?

    Leading companies operating in the choroidal neovascularization market are concentrating on developing innovative treatments, such as photodynamic therapy, to equip eye care professionals with precise and efficient options that enhance patient outcomes and treatment delivery. Photodynamic therapy (PDT) is a medical procedure utilizing a photosensitizing agent activated by light to specifically target and eliminate abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the ML6710i photodynamic laser, which gained approval from the Food and Drug Administration, a US-based federal agency. This therapy is approved for use with Bausch + Lomb’s VISUDYNE therapy, specifically designed to address choroidal neovascularization stemming from age-related macular degeneration (AMD). This modern, mobile ophthalmic laser provides a targeted strategy for treating abnormal blood vessels in the eye, contributing to the prevention of further disease progression and the preservation of vision.

    Which Major Firms Are Strengthening Their Position In The Choroidal Neovascularization Market?

    Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    Which Regions Are Poised For Strategic Growth In The Choroidal Neovascularization Market?

    North America was the largest region in the choroidal neovascularization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Choroidal Neovascularization Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

    Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2026, By The Business Research Company

    Ocular Hypertension Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/ocular-hypertension-treatment-global-market-report

    Intravascular Ultrasound Market Report 2026

    https://www.thebusinessresearchcompany.com/report/intravascular-ultrasound-global-market-report

    Vascular Imaging Market Report 2026

    https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • How Will The Choroidal Neovascularization Market Expand At A CAGR Of 7.5% Through 2029?

    How Will The Choroidal Neovascularization Market Expand At A CAGR Of 7.5% Through 2029?

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    How Will The Choroidal Neovascularization Market Valuation Change Between Now And 2029?

    Over the past few years, the market size for choroidal neovascularization has seen considerable growth. The market valuation is anticipated to shift from $3.88 billion in 2024, to $4.18 billion in 2025, showcasing a compound annual growth rate (CAGR) of 7.7%. The substantial growth experienced in the past can be credited to factors such as a rise in sedentary lifestyle diseases, an increase in age-related macular degeneration instances, a spike in retinal diseases prevalence, a surge in the elderly population, increased eye care expenses, and larger education and screening programs.

    The market size for choroidal neovascularization is projected to experience significant growth in the upcoming years, expanding to $5.59 billion by 2029 with a 7.5% Compound Annual Growth Rate (CAGR). This anticipated growth during the forecast period is due to factors such as increased patient awareness, widespread use of optical coherence tomography angiography, a rising demand for minimally invasive procedures, advantageous reimbursement policies, and an increasing older adult population. Main trends predicted during the forecast period encompass the introduction of intravitreal anti-vascular endothelial (VEGF) therapies, innovative gene treatments, gene therapy techniques, incorporation of telemedicine, the formulation of combined therapies, and individualized treatment strategies.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

    What Growth-Enabling Forces Are Impacting The Choroidal Neovascularization Market?

    The choroidal neovascularization (CNV) market is anticipated to grow due to an increase in age-related macular degeneration (AMD). AMD is an eye disorder that progressively harms the macula, typically in older individuals, leading to loss of central vision. The surge in AMD cases can be attributed to an aging populace, improved lifespan, changes in lifestyle, genetic predisposition, and increased environmental risk exposure. CNV helps support individuals with AMD by promoting the onset of wet AMD – characterised by the growth of abnormal blood vessels under the retina that causes vision to deteriorate. Advanced treatments like anti-VEGF therapy are often needed to manage CNV and slow down AMD progression, helping to maintain central eyesight in patients. The National Institutes of Health, a US governmental agency, reported in September 2022 that the number of AMD cases might rise to 300 million by 2040 and 5.4 million Americans could be impacted by 2050. Consequently, this rising pattern of AMD is bolstering the growth of the CNV market.

    What Are The Main Segment Classifications In The Choroidal Neovascularization Market?

    The choroidal neovascularizationmarket covered in this report is segmented –

    1) By Treatment Type: Anti-Angiogenic Therapy; Laser Photocoagulation; Photodynamic Therapy; Verteporfin Sodium; Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium

    2) By Indication: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME); Central Serous Chorioretinopathy (CSC); Polypoidal Choroidal Vasculopathy (PCV); Myopic Macular Degeneration (MMD); Other Indications

    3) By Route Of Administration: Intravitreal; Subconjunctival; Periocular; Oral

    4) By End User: Hospitals; Ophthalmology Clinics; Ambulatory Surgical Centers; Research Centers

    Subsegments:

    1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium

    2) By Laser Photocoagulation: Thermal Laser Photocoagulation; MicroPulse Laser Therapy

    3) By Photodynamic Therapy (PDT): Standard PDT; Low-Fluence PDT; Half-Dose PDT

    4) By Verteporfin Sodium: Intravenous Administration; Combination Therapy With Anti-VEGF

    5) By Ranibizumab: Monthly Dosing; As-Needed Dosing; Treat-and-Extend Regimen

    6) By Bevacizumab: Off-Label Use; Compounded Intravitreal Injections

    7) By Aflibercept: Fixed-Dosing Regimen; Treat-and-Extend Regimen

    8) By Pegaptanib Sodium: Monotherapy; Combination Therapy

    How Are Industry Trends Steering The Expansion Of The Choroidal Neovascularization Market?

    Leaders in the choroidal neovascularization industry are putting their efforts towards creating cutting-edge therapies such as photodynamic therapy, aiming to offer eye care practitioners effective, meticulous treatment choices that boost patient satisfaction and treatment administration. Photodynamic therapy (PDT) is a clinical procedure that involves the use of a photosensitive agent, activated by light, to eradicate abnormal or malignant cells. For example, in February 2023, Bausch & Lomb, a healthcare firm based in Canada, together with Modulight, a biomedical company from Finland, declared that their ML6710i photodynamic laser received approval from the Food and Drug Administration, a regulatory body in the United States. This therapeutic procedure, in conjunction with Bausch + Lomb’s VISUDYNE therapy, received approval for the treatment of choroidal neovascularization caused by age-related macular degeneration (AMD). This novel, mobile eye laser presents a targeted method for treating unusual blood vessels found in the eye, which serves as a preemptive measure against further progression of the disease, and maintaining eyesight.

    Which Firms Are Driving Innovation Within The Choroidal Neovascularization Market?

    Major companies operating in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    What Are The Emerging Regional Trends Driving The Choroidal Neovascularization Market?

    North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

    Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2025, By The Business Research Company

    Myopia And Presbyopia Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/myopia-and-presbyopia-treatment-global-market-report

    Warship And Naval Vessels Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/warship-and-naval-vessels-global-market-report

    Fiber Reinforced Plastic Vessels Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/fiber-reinforced-plastic-vessels-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Choroidal Neovascularization Market Expansion Outlook: $5.59 Billion by 2029 Forecast

    Choroidal Neovascularization Market Expansion Outlook: $5.59 Billion by 2029 Forecast

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    #What Is The Projected Market Size Of The Choroidal Neovascularization Market By 2029?

    The choroidal neovascularization market size has seen substantial growth over recent years. It is anticipated to expand from $3.88 billion in 2024 to $4.18 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.7%. This expansion in the past can be attributed to the increasing spread of sedentary lifestyle diseases, a growing prevalence of age-related macular degeneration, the rising occurrence of retinal illnesses, an expanding aged population, escalating eye care costs, and broader education and screening initiatives.

    The choroidal neovascularization market is projected to experience substantial expansion in the coming years, set to reach $5.59 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.5%. Several factors will drive this growth during the forecast period, including heightened patient awareness, the increasing uptake of optical coherence tomography angiography, rising demand for minimally invasive treatments, supportive reimbursement frameworks, and an expanding elderly demographic. Key trends anticipated during this period encompass the introduction of intravitreal anti-vascular endothelial (VEGF) therapies, novel gene treatments, diverse gene therapy methodologies, the integration of telemedicine, the creation of combination therapies, and tailored treatment plans.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

    Which Drivers Are Impacting The Choroidal Neovascularization Market?

    The escalating occurrence of age-related macular degeneration (AMD) is anticipated to fuel the expansion of the choroidal neovascularization (CNV) market moving ahead. Age-related macular degeneration (AMD) is an ocular condition that progressively impairs the macula, resulting in the loss of central vision, predominantly among older individuals. The increasing incidence of age-related macular degeneration (AMD) stems from an aging demographic, extended lifespans, evolving lifestyle patterns, genetic predispositions, and heightened exposure to environmental hazards. Choroidal neovascularization (CNV) plays a role in assisting age-related macular degeneration (AMD) patients by facilitating the emergence of wet AMD, a condition where abnormal blood vessel proliferation under the retina leads to visual decline. This necessitates advanced interventions like anti-VEGF therapy to control choroidal neovascularization (CNV) and impede the advancement of age-related macular degeneration (AMD), thereby aiming to maintain central vision for those affected. As an illustration, in September 2022, data from the National Institutes of Health, a US-based government agency, indicated that by 2040, age-related macular degeneration (AMD) instances might reach 300 million, and by 2050, 5.4 million Americans could be affected. Consequently, the growing prevalence of age-related macular degeneration is propelling the development of the choroidal neovascularization market.

    How Is The Choroidal Neovascularization Market Segmented?

    The choroidal neovascularizationmarket covered in this report is segmented –

    1) By Treatment Type: Anti-Angiogenic Therapy; Laser Photocoagulation; Photodynamic Therapy; Verteporfin Sodium; Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium

    2) By Indication: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME); Central Serous Chorioretinopathy (CSC); Polypoidal Choroidal Vasculopathy (PCV); Myopic Macular Degeneration (MMD); Other Indications

    3) By Route Of Administration: Intravitreal; Subconjunctival; Periocular; Oral

    4) By End User: Hospitals; Ophthalmology Clinics; Ambulatory Surgical Centers; Research Centers

    Subsegments:

    1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium

    2) By Laser Photocoagulation: Thermal Laser Photocoagulation; MicroPulse Laser Therapy

    3) By Photodynamic Therapy (PDT): Standard PDT; Low-Fluence PDT; Half-Dose PDT

    4) By Verteporfin Sodium: Intravenous Administration; Combination Therapy With Anti-VEGF

    5) By Ranibizumab: Monthly Dosing; As-Needed Dosing; Treat-and-Extend Regimen

    6) By Bevacizumab: Off-Label Use; Compounded Intravitreal Injections

    7) By Aflibercept: Fixed-Dosing Regimen; Treat-and-Extend Regimen

    8) By Pegaptanib Sodium: Monotherapy; Combination Therapy

    What Trends Are Redefining The Choroidal Neovascularization Market Dynamics?

    Major companies within the choroidal neovascularization market are concentrating on developing innovative treatments, including photodynamic therapy, to provide eye care professionals with precise, efficient options that enhance patient outcomes and improve treatment delivery. Photodynamic therapy (PDT) is a medical process that employs a photosensitizing agent activated by light to pinpoint and eliminate abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the ML6710i photodynamic laser had received approval from the Food and Drug Administration, a US-based federal agency. This therapy is sanctioned for use with Bausch + Lomb’s VISUDYNE therapy, which is specifically designed to treat choroidal neovascularization caused by age-related macular degeneration (AMD). This contemporary, mobile ophthalmic laser offers a targeted approach for addressing abnormal blood vessels in the eye, thereby contributing to preventing further disease progression and preserving vision.

    Which Major Firms Are Strengthening Their Position In The Choroidal Neovascularization Industry?

    Major companies operating in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    What Regional Growth Trends Are Shaping The Choroidal Neovascularization Market Outlook?

    North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Choroidal Neovascularization Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

    Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2025, By The Business Research Company

    Myopia And Presbyopia Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/myopia-and-presbyopia-treatment-global-market-report

    Warship And Naval Vessels Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/warship-and-naval-vessels-global-market-report

    Fiber Reinforced Plastic Vessels Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/fiber-reinforced-plastic-vessels-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Choroidal Neovascularization Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

    Choroidal Neovascularization Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Are the Key Projections for the CAGR of the Choroidal Neovascularization Market Size From 2025 to 2034?

    In recent times, the market size for choroidal neovascularization has experienced robust growth. It is projected to escalate from $3.88 billion in 2024 to $4.18 billion in 2025, with a compound annual growth rate (CAGR) of 7.7%. Factors contributing to the growth in the past period include the surge in diseases related to a sedentary lifestyle, an increase in age-related macular degeneration cases, a higher number of retinal illness occurrences, an aging population, increasing expenses in eye care, and extensive efforts in education and screening.

    The market for choroidal neovascularization is predicted to experience a significant surge in the coming years, set to expand to$5.59 billion by 2029 with a compound annual growth rate (CAGR) of 7.5%. The augmented development during the forecast period can be linked to factors like heightened patient consciousness, elevated usage of optical coherence tomography angiography, increased need for minimally invasive processes, positive reimbursement schemes, and an aging population. The forecast period will also see key trends such as the rise in intravitreal anti-vascular endothelial (VEGF) treatments, the introduction of new gene therapies, advancements in gene therapy approaches, the utilization of telemedicine, the formulation of combination therapies, and the creation of customized treatment plans.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

    What Are the Core Growth Drivers Propelling the Choroidal Neovascularization Market Forward?

    Expectations for the choroidal neovascularization (CNV) market’s advancement are fueled by escalating instances of age-related macular degeneration (AMD). AMD is an ocular disorder that progressively impairs the macula, leading to loss of central vision, primarily amongst elderly adults. The surge in AMD rates can be attributed to an aging population, prolonged lifespan, transformations in lifestyle, genetic elements, and greater exposure to environmental hazards. CNV aids patients suffering from AMD by facilitating the development of wet AMD, which is characterized by the growth of irregular blood vessels beneath the retina that lead to a decline in vision and necessitate complex treatments such as anti-VEGF therapy. This therapy serves to manage CNV and decelerate the progression of AMD, thereby preserving central vision in affected individuals. For instance, the National Institutes of Health, a government agency based in the US, reported in September 2022 that by 2040, AMD cases may rise to 300 million and by 2050, 5.4 million Americans might be impacted. Therefore, the escalating instances of AMD are contributing to the growth of the CNV market.

    What Segment Types Define the Choroidal Neovascularization Market Structure?

    The choroidal neovascularizationmarket covered in this report is segmented –

    1) By Treatment Type: Anti-Angiogenic Therapy; Laser Photocoagulation; Photodynamic Therapy; Verteporfin Sodium; Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium

    2) By Indication: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME); Central Serous Chorioretinopathy (CSC); Polypoidal Choroidal Vasculopathy (PCV); Myopic Macular Degeneration (MMD); Other Indications

    3) By Route Of Administration: Intravitreal; Subconjunctival; Periocular; Oral

    4) By End User: Hospitals; Ophthalmology Clinics; Ambulatory Surgical Centers; Research Centers

    Subsegments:

    1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium

    2) By Laser Photocoagulation: Thermal Laser Photocoagulation; MicroPulse Laser Therapy

    3) By Photodynamic Therapy (PDT): Standard PDT; Low-Fluence PDT; Half-Dose PDT

    4) By Verteporfin Sodium: Intravenous Administration; Combination Therapy With Anti-VEGF

    5) By Ranibizumab: Monthly Dosing; As-Needed Dosing; Treat-and-Extend Regimen

    6) By Bevacizumab: Off-Label Use; Compounded Intravitreal Injections

    7) By Aflibercept: Fixed-Dosing Regimen; Treat-and-Extend Regimen

    8) By Pegaptanib Sodium: Monotherapy; Combination Therapy

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

    Which Geographic Areas Hold the Strongest Growth Potential in the Choroidal Neovascularization Market?

    North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Which Emerging Trends that Are Influencing theChoroidal Neovascularization Industry Evolution?

    Leading organizations in the choroidal neovascularization market are directing their efforts on the development of novel therapies, such as photodynamic therapy, targeting the provision of exact and effective treatment choices to eye care professionals, thereby leading to improved patient results and streamlined treatment. Photodynamic therapy (PDT) is a medicinal procedure utilizing a photosensitizing agent activated via light to eliminate unusual or cancerous cells. In a practical example, Bausch & Lomb, a Canadian healthcare enterprise, in collaboration with Modulight, a biomedical firm based in Finland, announced in February 2023, the approval of ML6710i photodynamic laser by the Food and Drug Administration, a US federal agency. This treatment approval is specific to its application in conjunction with Bausch + Lomb’s VISUDYNE therapy, a treatment designed specifically for choroidal neovascularization resulting from age-related macular degeneration (AMD). This state-of-the-art portable ophthalmic laser delivers a focused method for addressing abnormal eye blood vessels, aiding in the prevention of further disease advancement and the preservation of visual acuity.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    What Is the Definition of the Choroidal Neovascularization Market?

    Choroidal neovascularization (CNV) is the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These newly formed blood vessels are fragile and prone to leaking fluid or blood, which can damage the retinal tissues, leading to vision distortion or loss.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21142

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Market Analysis on Choroidal Neovascularization Industry – Insights for Corporate Strategy and R&D

    Market Analysis on Choroidal Neovascularization Industry – Insights for Corporate Strategy and R&D

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Forecast for the Choroidal Neovascularization Market from 2024 to 2025?

    The market for choroidal neovascularization has seen robust growth in the past few years. It is projected to expand from $3.37 billion in 2024, to $3.61 billion in 2025, clocking a compound annual growth rate (CAGR) of 8.1%. The growth witnessed in the past can be credited to factors such as an increase in diseases related to sedentary lifestyles, a rise in age-related macular degeneration cases, increasing incidence of illnesses related to the retina, the aging population, escalating costs of eye care, and broadening education and screening initiatives.

    What Is the Projected Market Size of the Choroidal Neovascularization Market?

    Strong expansion is expected in the choroidal neovascularization market in the coming years. The market is projected to climb to $5.64 billion by 2029, with a compound annual growth rate (CAGR) of 7.7%. The rise during the forecast period can be credited to greater patient awareness, the increasing use of optical coherence tomography angiography, an escalating demand for less invasive procedures, beneficial reimbursement policies, and a swelling geriatric population. Noteworthy trends for the forecast period incorporate the advent of intravitreal anti-vascular endothelial (VEGF) therapies, innovative gene treatments, gene therapy methodologies, the adoption of telemedicine, the development of combined therapies, and customized treatment strategies.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

    Who are the Major Competitors in the Choroidal Neovascularization Market Outlook?

    Major companies operating in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

    What Is Fueling Growth in the Choroidal Neovascularization Market?

    The growth of the choroidal neovascularization (CNV) market is anticipated to be driven by the increasing occurrence of age-related macular degeneration (AMD). AMD is an ocular condition that gradually impairs the macula, resulting in loss of central vision, predominantly in the elderly. The escalating instances of AMD can be attributed to demographics aging, extended lifespan, lifestyle shifts, genetics, and heightened exposure to environmental hazards. CNV aids AMD patients by facilitating the onset of wet AMD, characterized by the proliferation of abnormal blood vessels below the retina causing vision impairment. Advanced treatments such as anti-VEGF therapy are required to control CNV and slow down the progression of AMD, thereby safeguarding the central vision in affected persons. According to data from the National Institutes of Health, a government agency in the US, in September 2022, it is projected that by 2040, AMD cases may touch 300 million and by 2050, 5.4 million Americans may be impacted. Consequently, the escalating occurrence of AMD is propelling the growth of the choroidal neovascularization market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

    Which Choroidal Neovascularization Market Segments Are Growing the Fastest?

    The choroidal neovascularization market covered in this report is segmented –

    1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

    3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

    4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

    Subsegments:

    1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

    3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

    4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

    5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

    6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

    7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

    8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

    Which Industry Trends Are Shaping the Future of the Choroidal Neovascularization Market?

    Key players in the choroidal neovascularization market are endeavoring to develop innovative therapeutic solutions, including photodynamic therapy, aiming to offer accurate and efficient treatment alternatives that enhance patient results and treatment execution. Photodynamic therapy (PDT) is a clinical procedure that employs a photosensitizing agent, activated by light, to eliminate abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a health care firm based in Canada, along with Modulight, a biomedical firm from Finland, unveiled the ML6710i photodynamic laser that received approval from the Food and Drug Administration, a U.S. federal agency. This approach is sanctioned for use in conjunction with Bausch + Lomb’s VISUDYNE therapy, developed to treat age-related macular degeneration (AMD)-induced choroidal neovascularization. The cutting-edge, portable ophthalmic laser enables a precise methodology to manage abnormal ocular blood vessels, aiding in halting disease advancement and maintaining vision.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    Which Countries Are Leading the Choroidal Neovascularization Market?

    North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21142

    This Report Delivers Insight On:

    1. How big is the choroidal neovascularization market, and how is it changing globally?

    2. Who are the major companies in the choroidal neovascularization market, and how are they performing?

    3. What are the key opportunities and risks in the choroidal neovascularization market right now?

    4. Which products or customer segments are growing the most in the choroidal neovascularization market?

    5. What factors are helping or slowing down the growth of the choroidal neovascularization market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 2071930708

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Choroidal Neovascularization Market Trends: Regional Breakdowns and Strategic Insights

    Global Choroidal Neovascularization Market Trends: Regional Breakdowns and Strategic Insights

    Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

    What Is the Estimated Market Size of the Choroidal Neovascularization Market In 2029?

    In the recent past, the market size for choroidal neovascularization has seen robust growth. An expected increase from $3.37 billion in 2024 to $3.61 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%, is predicted. The historical period’s advancement can be credited to the increasing spread of diseases linked to inactive lifestyles, a growing case of age-related macular degeneration, an increase in retinal disease cases, an aging population, escalating costs for eye care, and the expansion of education and screening programs.

    The market size for choroidal neovascularization is projected to see robust growth over the coming years, increasing to $5.64 billion in 2029 with a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period is credited to heightened patient awareness, amplified adoption of optical coherence tomography angiography, rising demand for minimally invasive procedures, agreeable reimbursement policies, and an expanding elderly populace. Key trends forecasted in this period include the advent of intravitreal anti-vascular endothelial (VEGF) treatments, innovative gene therapies and approaches, the implementation of telemedicine, the creation of combination therapies, and personalized treatment plans.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

    What Are the Major Market Drivers Behind the Rising Adoption of Choroidal Neovascularization Market?

    The growth of the choroidal neovascularization (CNV) market is anticipated to be fueled by the rising instances of age-related macular degeneration (AMD). AMD, an eye disease often seen in the elderly, gradually impairs the macula, resulting in the loss of central vision. This increase in AMD cases can be attributed to factors such as an aging population, increased lifespan, changes in lifestyle, hereditary factors, and heightened exposure to environmental hazards. CNV aids in managing AMD by contributing to the onset of the wet form of AMD, which is characterized by the growth of abnormal blood vessels beneath the retina, causing declining vision that necessitates advanced treatments like anti-VEGF therapy. Such treatments help manage CNV and delay the progression of AMD, thereby preserving central vision in those affected. To illustrate, the National Institutes of Health, a government agency based in the United States, has estimated that by 2040, the number of AMD cases could hit 300 million, and by 2050, as many as 5.4 million Americans could be affected. Therefore, the escalating rate of AMD is stimulating the growth of the CNV market.

    Which Key Market Segments Comprise the Choroidal Neovascularization Market and Drive Its Revenue Growth?

    The choroidal neovascularization market covered in this report is segmented –

    1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

    3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

    4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

    Subsegments:

    1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

    2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

    3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

    4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

    5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

    6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

    7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

    8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

    Which Areas Are Leading Regions in the Choroidal Neovascularization Market Expansion Across the Globe?

    North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Strategic Trends Steering theChoroidal Neovascularization Market Direction?

    Leading corporations in the choroidal neovascularization market are honing in on the development of innovative treatments such as photodynamic therapy, with the aim of providing eye care experts with precise and effective treatment alternatives that enhance patient results and treatment provision. Photodynamic therapy (PDT) is a medicinal procedure that utilizes light to activate a photosensitizing agent, which in turn targets and eradicates unusual or cancerous cells. As an illustration, Bausch & Lomb, a healthcare firm based in Canada, and Modulight, a biomedical company in Finland, proclaimed in February 2023 the Food and Drug Administration’s (a US-based government agency) endorsement of the ML6710i photodynamic laser. Its approval paves the way for its utilization with Bausch + Lomb’s VISUDYNE therapy, which has been created to counter choroidal neovascularization, an issue stemming from age-related macular degeneration (AMD). This advanced, portable ophthalmic laser devises a strategic plan for managing abnormal blood vessels in the eye, thereby halting further disease development and safeguarding vision.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

    How Is the Choroidal Neovascularization Market Conceptually Defined?

    Choroidal neovascularization (CNV) is the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These newly formed blood vessels are fragile and prone to leaking fluid or blood, which can damage the retinal tissues, leading to vision distortion or loss.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21142

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model